Colorectal cancer risk remains despite modern treatment for ulcerative colitis

byKarolinska InstitutetJonas Ludvigsson, professor in the Department of Medical Epidemiology and Biostatistics at Karolinska Institutet in Sweden. Credit: Gustav MårtenssonPatients with the infl

Updated on: December 20,2023

Colorectal cancer risk remains despite modern treatment for ulcerative colitis

byKarolinska InstitutetJonas Ludvigsson, professor in the Department of Medical Epidemiology and Biostatistics at Karolinska Institutet in Sweden. Credit: Gustav MårtenssonPatients with the infl

Updated on:December 20,2023

Novel Genes Linked to Increased Breast Cancer Risk Discovered

byColleen Fleisson August 20, 2023Recently discovered genes linked tobreast cancermay eventually be incorporated into screening tests to detect higher risk levels in women .Bre

Updated on: December 19,2023

Novel Genes Linked to Increased Breast Cancer Risk Discovered

byColleen Fleisson August 20, 2023Recently discovered genes linked tobreast cancermay eventually be incorporated into screening tests to detect higher risk levels in women .Bre

Updated on:December 19,2023

Targeting specific genomic mutation in breast cancer improves outcomes, first study shows

byEuropean Society for Medical OncologyFabrice André, oncologist and Professor of Medical Oncology at the Institut Gustave Roussy, Villejuif, France, study author. Credit: © European Society for

Updated on: December 18,2023

Targeting specific genomic mutation in breast cancer improves outcomes, first study shows

byEuropean Society for Medical OncologyFabrice André, oncologist and Professor of Medical Oncology at the Institut Gustave Roussy, Villejuif, France, study author. Credit: © European Society for

Updated on:December 18,2023

As cancer deaths decline, access to care remains a challenge in some US communities

by Alex Osiadacz,Mayo ClinicCredit: Unsplash/CC0 Public DomainCancer remains the second-leading cause of death in the U.S., but the number of people dying from cancer continues to decline. In th

Updated on: January 04,2024

As cancer deaths decline, access to care remains a challenge in some US communities

by Alex Osiadacz,Mayo ClinicCredit: Unsplash/CC0 Public DomainCancer remains the second-leading cause of death in the U.S., but the number of people dying from cancer continues to decline. In th

Updated on:January 04,2024

Multimodal genomic analyses predict response to immunotherapy in lung cancer patients

by Amy Mone,Johns Hopkins University School of MedicineLung cancer. Credit: Jennifer Fairman and Valsamo Anagnostou, Johns Hopkins UniversityResearchers at Johns Hopkins Kimmel Cancer Center, th

Updated on: December 20,2023

Multimodal genomic analyses predict response to immunotherapy in lung cancer patients

by Amy Mone,Johns Hopkins University School of MedicineLung cancer. Credit: Jennifer Fairman and Valsamo Anagnostou, Johns Hopkins UniversityResearchers at Johns Hopkins Kimmel Cancer Center, th

Updated on:December 20,2023

Scientists aim to repair or replace p53 to combat cancer

Updated on: April 17,2025

Scientists aim to repair or replace p53 to combat cancer

Updated on:April 17,2025

Deep Learning in Cancer: Redefining Diagnosis, Prognosis, and Precision Oncology

Updated on: May 28,2025

Deep Learning in Cancer: Redefining Diagnosis, Prognosis, and Precision Oncology

Updated on:May 28,2025

Olaparib and adavosertib work best when given sequentially for DNA-damage response mutations in advanced tumors

by European Organisation for Research and Treatment of CancerCredit: Pixabay/CC0 Public DomainPatients with cancers that are driven by certain mutations occurring in response to DNA damage can be safe

Updated on: December 19,2023

Olaparib and adavosertib work best when given sequentially for DNA-damage response mutations in advanced tumors

by European Organisation for Research and Treatment of CancerCredit: Pixabay/CC0 Public DomainPatients with cancers that are driven by certain mutations occurring in response to DNA damage can be safe

Updated on:December 19,2023

Fixed-Duration Mosunetuzumab Elicits Durable Responses in R/R Follicular Lymphoma

June 27, 2023Kristi RosaFixed-duration treatment with single-agent mosunetuzumab resulted in a high complete response rate by end of treatment in patients with relapsed or refractory follicular lympho

Updated on: October 15,2023

Fixed-Duration Mosunetuzumab Elicits Durable Responses in R/R Follicular Lymphoma

June 27, 2023Kristi RosaFixed-duration treatment with single-agent mosunetuzumab resulted in a high complete response rate by end of treatment in patients with relapsed or refractory follicular lympho

Updated on:October 15,2023

Iruplinalkib Improves PFS Vs Crizotinib in Locally Advanced or Metastatic ALK+ NSCLC

September 10, 2023Kristi RosaTreatment with iruplinalkib significantly improved progression-free survival and produced a higher objective response rate compared with crizotinib in patients with ALK TK

Updated on: October 11,2023

Iruplinalkib Improves PFS Vs Crizotinib in Locally Advanced or Metastatic ALK+ NSCLC

September 10, 2023Kristi RosaTreatment with iruplinalkib significantly improved progression-free survival and produced a higher objective response rate compared with crizotinib in patients with ALK TK

Updated on:October 11,2023

More proof that concurrent use of multiple medications leads to adversity for older cancer patients

byUniversity of Rochester Medical CenterCredit: Pixabay/CC0 Public DomainWhen older adults with cancer take multiple medications—including ordinary drugs like blood pressure pills, supplements,

Updated on: December 22,2023

More proof that concurrent use of multiple medications leads to adversity for older cancer patients

byUniversity of Rochester Medical CenterCredit: Pixabay/CC0 Public DomainWhen older adults with cancer take multiple medications—including ordinary drugs like blood pressure pills, supplements,

Updated on:December 22,2023

Targeted lung cancer drug shows promise in phase I/II clinical trial

by European Organisation for Research and Treatment of CancerCredit: Pixabay/CC0 Public DomainEarly trials of the targeted drug repotrectinib suggest that it could help treat patients with a certain t

Updated on: December 19,2023

Targeted lung cancer drug shows promise in phase I/II clinical trial

by European Organisation for Research and Treatment of CancerCredit: Pixabay/CC0 Public DomainEarly trials of the targeted drug repotrectinib suggest that it could help treat patients with a certain t

Updated on:December 19,2023